Helsinn Group and Eisai Inc. announce start of phase III clinical program of oral fixed-dose combination of Netupitant/Palonosetron (300mg/0.50mg) for prevention of CINV
Lugano, Switzerland and Woodcliff Lake, NJ, USA (ots) - Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and ...